Clinical Trial Update: Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702 [Phase 2]

View source ↗

Summary

The document reports the completion of a Phase 2 clinical trial evaluating the investigational p38 MAP kinase inhibitor VX-702 for rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• VX-702

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED